<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="360">
  <stage>Registered</stage>
  <submitdate>2/09/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <actrnumber>ACTRN12605000324617</actrnumber>
  <trial_identification>
    <studytitle>A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN I &amp; ATTAIN II)</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN I &amp; ATTAIN II)</scientifictitle>
    <utrn />
    <trialacronym>ATTAIN I &amp; ATTAIN II</trialacronym>
    <secondaryid>0015</secondaryid>
    <secondaryid>0019</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hospital-Acquired Pneumonia</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Telavancin 10 mg/kg q 24 hours IV</interventions>
    <comparator>Vancomycin 1 Gm q 12 hours IV</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical response at test of cure evaluation</outcome>
      <timepoint>Performed 7 to 14 days following completion of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability</outcome>
      <timepoint>Baseline, q 3d, End of Therapy and Test of Cure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of hospital acquired pneumonia.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>More than 24 hours of prior therapy unless a treatment failure. Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomized treatment assigments are provided to the site pharmacist following enrollment of each patient using a centralized enrollment resource. The site pharmacist prepares the study treatments and they are labeled for administration in a blinded fashion per a site specific blinding plan.</concealment>
    <sequence>SAS programming was utilized to generate a blocked, stratified random allocation sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/02/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>750</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Theravance, Inc.</primarysponsorname>
    <primarysponsoraddress>901 Gateway Blvd, South San Francisco, CA, USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Theravance, Inc</fundingname>
      <fundingaddress>901 Gateway Blvd, South San Francisco, CA, USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. David Friedland</name>
      <address>Theravance Inc.
901 Gateway Blvd.
South San Francisco CA 94080</address>
      <phone>+1 650 8084063</phone>
      <fax />
      <email>dsharp@theravance.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Denise Sharp</name>
      <address>Theravance Inc.
901 Gateway Blvd.
South San Francisco CA 94080</address>
      <phone>+1 650 8084072</phone>
      <fax />
      <email>dfriedland@theravance.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>